Feline Osteoarthritis: Diagnosis and Management

Feline osteoarthritis (OA) is a progressive, degenerative joint disease with high prevalence in the domestic cat population, particularly in animals over ten years of age. Diagnosis requires systematic integration of history, physical examination, diagnostic imaging, and validated pain assessment tools. Effective management depends on a multimodal approach addressing pain, inflammation, joint health, body weight, and environmental adaptation. This article provides veterinary clinicians with a practical, evidence-informed framework for diagnosing and managing feline OA, emphasizing objective assessment and individualized treatment planning.

At a Glance: Feline Osteoarthritis Diagnosis and Management

Pathophysiology of Feline Osteoarthritis

Feline OA is characterized by progressive loss of articular cartilage, synovial inflammation, and remodeling of subchondral bone. Unlike in dogs, the disease in cats often develops without a clear inciting cause, with primary (idiopathic) OA being common. Secondary OA can result from trauma, developmental abnormalities such as hip dysplasia, or previous joint infection. The pathophysiology involves mechanical stress, enzymatic degradation of cartilage matrix, and release of pro-inflammatory cytokines. This process leads to pain, joint stiffness, and functional impairment. The Merck Veterinary Manual provides a general overview of degenerative joint disease in cats. [4]

A 2025 review in the Journal of Feline Medicine and Surgery notes that despite decades of research, fundamental questions remain about the natural history of feline OA, including why some cats develop severe radiographic changes without apparent clinical signs while others with mild changes show significant impairment. [8] This discrepancy underscores the importance of individual assessment instead of relying solely on imaging findings.

Clinical Signs and Owner Observations

Cats with OA often exhibit subtle behavioral changes instead of overt lameness. Common signs include reduced activity, reluctance to jump onto furniture or into high-sided litter boxes, stiffness after rest, and decreased grooming of the hindquarters. Owners may report that the cat is "slowing down" or "sleeping more." These signs are frequently attributed to normal aging, leading to underdiagnosis. The 2021 AAFP Feline Senior Care Guidelines emphasize the importance of a thorough history and owner education to recognize these changes. [7]

Clinicians should specifically ask about the cat's ability to navigate stairs, access favorite resting spots, and use the litter box without difficulty. Changes in temperament, such as increased irritability or hiding, may also indicate chronic pain. A 2020 review in the Veterinary Clinics of North America highlights that behavioral changes are often the primary indicator of chronic pain in cats, as they rarely vocalize or limp. [9]

Differentiating OA from Other Causes of Mobility Impairment

Not all mobility impairment in cats is due to OA. Differential diagnoses include dental disease, neoplasia, neurologic conditions, and metabolic disorders such as hyperthyroidism. A 2016 case report in the Revista Brasileira de Medicina Veterinaria describes feline chronic progressive polyarthritis associated with FeLV infection, highlighting the need for thorough diagnostic workup. [13] Clinicians should perform a complete physical examination, including oral examination and neurologic assessment, before attributing clinical signs to OA.

Diagnostic Imaging

Radiography

Radiography remains the first-line imaging modality for diagnosing feline OA. Standard orthogonal views of the affected joint are required. Common findings include osteophyte formation, joint space narrowing, subchondral bone sclerosis, and periarticular new bone. The elbows, hips, stifles, and tarsi are most frequently affected. It is important to note that radiographic changes do not always correlate with the degree of pain or functional impairment. Some cats with severe radiographic OA may show minimal clinical signs, while others with mild changes may be significantly affected. The Merck Veterinary Manual discusses the use of radiography in diagnosing joint disease. [4]

A 2010 review in Topics in Companion Animal Medicine notes that radiography remains the most practical and widely available imaging modality for feline OA, despite its limitations in assessing soft tissue structures and early cartilage changes. [10] Clinicians should obtain at least two orthogonal views of each affected joint. Sedation is often necessary for proper positioning, particularly in painful or uncooperative cats.

Computed Tomography (CT)

CT provides superior detail of bony structures and is particularly useful for evaluating complex joints such as the elbow and tarsus. CT can detect subtle osteophytes, subchondral bone cysts, and joint incongruity that may be missed on radiographs. However, CT requires general anesthesia and is more expensive than radiography. Its use is typically reserved for cases where radiography is inconclusive or when surgical planning is needed. The ACVIM consensus statements on diagnostic imaging may offer further guidance. [3]

Advanced Imaging Considerations

Magnetic resonance imaging (MRI) is rarely used for routine OA diagnosis in cats but may be indicated when soft tissue pathology such as meniscal tears or synovitis is suspected. Referral to a veterinary imaging specialist is recommended for advanced imaging interpretation.

Pain Assessment Tools

Objective pain assessment is critical for diagnosing OA and monitoring treatment efficacy. The Feline Musculoskeletal Pain Index (FMPI) is a validated, owner-completed questionnaire that evaluates pain-related impairment in daily activities. It assesses domains such as mobility, grooming, and temperament. The FMPI can be administered at initial consultation and at follow-up visits to quantify response to therapy. Other tools include the Feline Grimace Scale and the Colorado State University Feline Acute Pain Scale, though these are more commonly used for acute pain. The 2021 AAFP Feline Senior Care Guidelines recommend routine pain assessment in senior cats. [7]

A 2023 review in the Veterinary Clinics of North America emphasizes that owner-completed questionnaires are essential for detecting subtle changes in behavior and activity that may not be apparent during a brief clinic visit. [6] Clinicians should incorporate these tools into their practice to standardize pain evaluation and track treatment outcomes over time.

Implementing Pain Scoring in Practice

• Administer the FMPI at initial consultation and at every recheck visit
• Provide the questionnaire to owners before the appointment to allow thoughtful responses
• Review responses with the owner to clarify any ambiguous answers
• Record scores in the medical record to track trends over time
• Use changes in scores to guide treatment adjustments

Multimodal Management

Effective management of feline OA requires a multimodal approach that targets pain, inflammation, joint health, and environmental factors. No single therapy is universally effective, and treatment plans must be individualized based on the cat's age, health status, and owner resources.

Weight Management

Obesity is a major risk factor for OA and exacerbates pain and functional impairment. Weight loss reduces mechanical load on joints and decreases systemic inflammation. A structured weight loss program, including dietary modification and controlled caloric restriction, should be initiated in overweight cats. The goal is a gradual, sustained weight loss of 1-2% of body weight per week. The Merck Veterinary Manual provides guidance on feline obesity management. [4]

Body condition score (BCS) should be assessed at every visit using a standardized 9-point scale. Cats with a BCS of 6 or higher should be placed on a weight loss plan. Owners should be counseled on portion control, feeding schedules, and the importance of eliminating free-choice feeding. Regular weigh-ins every 2-4 weeks help maintain accountability and allow adjustment of the plan as needed.

Environmental Modification

Environmental adaptations can significantly improve a cat's quality of life. Key modifications include providing ramps or steps to access elevated surfaces, using low-sided litter boxes, placing food and water bowls at ground level, and providing soft, padded bedding. These changes reduce the need for jumping and climbing, which are often painful for OA cats. The 2021 AAFP Feline Senior Care Guidelines emphasize the importance of environmental enrichment and accessibility. [7]

Specific recommendations include:

• Place litter boxes on the same floor level as the cat's primary living area
• Use litter boxes with low entry sides (less than 4 inches) or cut a lower entrance into a standard box
• Provide multiple resting areas with soft, orthopedic bedding
• Install ramps or pet stairs near furniture the cat previously jumped onto
• Keep food and water bowls at ground level or on a low platform
• Ensure easy access to favorite window perches or sunny spots

Analgesic Therapy

Pharmacologic management of OA pain in cats is challenging due to species-specific drug metabolism and a limited number of approved analgesics. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the mainstay of treatment, but only a few are approved for long-term use in cats. Meloxicam is the most commonly used NSAID, but it must be used with caution in cats with renal disease or dehydration. Other options include robenacoxib, which has a shorter half-life and may be safer for some patients. Gabapentin is frequently used as an adjunctive analgesic for neuropathic pain, though evidence for its efficacy in feline OA is limited. Amantadine may be considered for chronic pain, but its use is off-label. The 2021 AAFP Feline Senior Care Guidelines discuss analgesic options for chronic pain. [7]

Clinicians should always perform a thorough pre-treatment assessment, including renal function testing, and monitor for adverse effects. A 2020 review in the Veterinary Clinics of North America notes that many cats with OA have concurrent conditions such as chronic kidney disease or hyperthyroidism that influence drug selection and dosing. [9] Regular monitoring of renal parameters, liver enzymes, and clinical signs is essential for all cats receiving long-term NSAID therapy.

Biologic Therapies

Frunevetmab, a felinized anti-nerve growth factor (NGF) monoclonal antibody, is a newer treatment option for OA pain in cats. It works by neutralizing NGF, a key mediator of pain. A 2021 study in the Journal of Veterinary Internal Medicine demonstrated its efficacy in reducing pain and improving mobility in cats with OA. [11] Frunevetmab is administered as a monthly subcutaneous injection. It is generally well-tolerated, but potential adverse effects include injection site reactions and, rarely, hypersensitivity.

Another biologic approach is the use of platelet-rich plasma (PRP). A 2024 exploratory case series in Frontiers in Veterinary Science investigated PRP for degenerative joint disease in cats, showing potential benefits in pain reduction and functional improvement. [12] However, larger controlled studies are needed to confirm its efficacy and establish treatment protocols.

Joint Supplements

Joint supplements, also known as nutraceuticals, are commonly used as adjunctive therapy. Common ingredients include glucosamine, chondroitin sulfate, omega-3 fatty acids, and green-lipped mussel extract. Evidence for their efficacy in cats is mixed, with some studies showing modest benefits and others showing no effect. The Merck Veterinary Manual notes that while many supplements are marketed for joint health, rigorous clinical trials are lacking. [4]

Clinicians should discuss the potential benefits and limitations with owners and recommend products from reputable manufacturers. Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have the strongest evidence for anti-inflammatory effects in cats. Products should be sourced from companies that provide third-party testing for purity and potency.

Physical Therapy and Rehabilitation

Physical therapy can improve joint range of motion, muscle strength, and overall mobility. Modalities include passive range of motion exercises, therapeutic laser, and hydrotherapy. A rehabilitation plan should be tailored to the individual cat's tolerance and needs. The 2021 AAFP Feline Senior Care Guidelines highlight the role of rehabilitation in managing chronic pain. [7]

Referral to a veterinary rehabilitation specialist may be beneficial for complex cases. Home exercises, such as gentle joint flexion and extension, can be taught to owners. Therapeutic laser (photobiomodulation) has shown promise for reducing pain and inflammation in some studies, though evidence in cats remains limited.

Practical Implementation Steps

1. Initial Assessment: Obtain a detailed history, perform a complete physical and orthopedic examination, and administer a validated pain assessment tool such as the FMPI.
2. Diagnostic Imaging: Obtain orthogonal radiographs of affected joints. Consider CT for complex cases or when radiography is inconclusive.
3. Weight Management: Calculate BCS and initiate a weight loss plan if the cat is overweight or obese. Set a target weight and schedule regular weigh-ins.
4. Environmental Modification: Provide ramps, low-sided litter boxes, and soft bedding. Educate the owner on these changes and provide written instructions.
5. Pharmacologic Therapy: Select an appropriate analgesic based on the cat's health status and pain severity. Start with the lowest effective dose and monitor for adverse effects.
6. Adjunctive Therapies: Consider joint supplements, biologic therapies, or physical therapy as part of a multimodal plan.
7. Reassessment: Schedule regular follow-up visits every 4-8 weeks initially, then every 3-6 months once stable. Monitor pain scores, mobility, and quality of life. Adjust the treatment plan as needed.

Records and Measurements

Maintaining accurate records is essential for tracking disease progression and treatment response. Key data points include:

A standardized record form should include space for owner-reported changes, such as the cat's ability to jump, use the litter box, and interact with family members. Digital records allow for easy tracking of trends over time.

Common Failure Patterns

• Underdiagnosis: Attributing clinical signs to normal aging instead of OA. This is the most common reason for delayed treatment.
• Inadequate Pain Assessment: Relying solely on owner report without using validated tools. Owners may not recognize subtle signs of pain.
• Monotherapy: Using only one treatment modality, which is often insufficient for managing chronic pain.
• Poor Owner Compliance: Failure to implement environmental modifications or administer medications as prescribed. This is often due to lack of understanding or perceived inconvenience.
• Lack of Monitoring: Not scheduling regular rechecks to assess treatment response and adjust the plan. OA is a progressive disease that requires ongoing management.
• Inappropriate Drug Selection: Using analgesics that are not approved for cats or that have significant side effects in individual patients.

Limitations and Safety Context

• Radiographic-Pain Discrepancy: Radiographic severity does not always correlate with pain levels. Some cats with severe OA show minimal clinical signs, while others with mild changes are significantly impaired.
• Limited Pharmacologic Options: Few analgesics are approved for long-term use in cats, and many have significant side effects. The 2020 review in the Veterinary Clinics of North America notes that this limitation often forces clinicians to use off-label medications. [9]
• Off-Label Use: Many therapies, including gabapentin and amantadine, are used off-label. Clinicians should inform owners of this and document informed consent.
• Renal and Hepatic Function: Cats with impaired renal or hepatic function require careful drug selection and monitoring. NSAIDs are contraindicated in dehydrated or hypotensive cats.
• Owner Education: Owners may be reluctant to administer medications or make environmental changes. Clear communication about the benefits and risks is essential.
• Differential Diagnoses: Other causes of chronic pain and mobility impairment, such as dental disease, neoplasia, or neurologic conditions, should be ruled out. A 2016 case report in the Revista Brasileira de Medicina Veterinaria describes feline chronic progressive polyarthritis associated with FeLV infection, highlighting the need for thorough diagnostic workup. [13]

Professional Escalation Criteria

• Uncontrolled Pain: If pain is not adequately controlled with first-line therapies after 4-6 weeks, consider referral to a veterinary pain specialist or rehabilitation center.
• Suspected Surgical Disease: If there is evidence of a joint fracture, luxation, or other surgical condition, refer to a veterinary surgeon.
• Adverse Drug Reactions: If a cat experiences a severe adverse reaction to a medication, discontinue the drug and provide supportive care. Consult with a veterinary pharmacologist or internist.
• Diagnostic Uncertainty: If the diagnosis is unclear or if imaging findings are equivocal, consider referral for advanced imaging (CT or MRI) or a second opinion.
• Concurrent Disease: If the cat has significant concurrent conditions such as chronic kidney disease, hyperthyroidism, or diabetes mellitus, consult with a veterinary internist for coordinated management.
• Owner Concerns: If the owner is unable or unwilling to implement the recommended treatment plan, consider referral for behavioral counseling or social work support.

Practical Decision Framework for Selecting and Adjusting Feline Osteoarthritis Therapies

Selecting the right combination of therapies for an individual cat with osteoarthritis requires a structured decision framework that accounts for disease severity, concurrent conditions, owner capabilities, and treatment response. Without a systematic approach, clinicians risk using ineffective monotherapy, failing to recognize inadequate pain control, or exposing cats to unnecessary adverse effects. This section provides a practical, step-by-step decision framework that integrates patient assessment, treatment selection, monitoring, and adjustment protocols. The framework is designed to be used at initial diagnosis and at every recheck visit.

Tiered Treatment Selection Based on Disease Severity

A tiered approach helps clinicians match treatment intensity to disease severity. This framework uses three tiers based on the Feline Musculoskeletal Pain Index (FMPI) score, physical examination findings, and owner-reported functional impairment. The 2023 review in the Veterinary Clinics of North America emphasizes that treatment should be individualized and escalated based on response. [6]

Tier 1: Mild OA (FMPI score 0-15, minimal physical exam findings, owner reports subtle changes)

First-line interventions for mild OA focus on non-pharmacologic measures. These interventions have the lowest risk of adverse effects and can be implemented by most owners.

• Initiate a weight management plan if the cat has a body condition score of 6 or higher on the 9-point scale. Set a target weight and schedule weigh-ins every 2-4 weeks. The Merck Veterinary Manual provides guidance on feline obesity management. [4]
• Implement environmental modifications: provide ramps or steps to favorite resting spots, use low-sided litter boxes, place food and water bowls at ground level, and add soft orthopedic bedding in multiple locations.
• Start a joint supplement containing omega-3 fatty acids (EPA and DHA). Choose products from manufacturers that provide third-party testing for purity and potency.
• Educate the owner on recognizing subtle signs of pain and the importance of maintaining the environmental changes.
• Schedule a recheck in 4-6 weeks to reassess pain scores and functional status.

Tier 2: Moderate OA (FMPI score 16-30, palpable joint changes, owner reports clear functional impairment)

For cats with moderate OA, add pharmacologic therapy to the Tier 1 interventions. The goal is to achieve adequate pain control while minimizing adverse effects.

• Continue all Tier 1 interventions.
• Add an NSAID approved for long-term use in cats. Meloxicam oral suspension is commonly used, starting at 0.05 mg/kg once daily. Robenacoxib is an alternative with a shorter half-life. Perform pre-treatment renal function testing and ensure the cat is well-hydrated. The 2021 AAFP Feline Senior Care Guidelines discuss NSAID use in senior cats. [7]
• Consider adding gabapentin as an adjunctive analgesic, starting at 5-10 mg/kg every 8-12 hours. Gabapentin is used off-label for neuropathic pain, though evidence for its efficacy in feline OA is limited. Monitor for sedation and ataxia, particularly in the first few days of therapy.
• Recheck in 4 weeks. Assess pain scores, renal function (if on NSAIDs), and owner satisfaction. Adjust doses or change medications if pain is not adequately controlled or if adverse effects occur.

Tier 3: Severe OA (FMPI score 31-45, marked radiographic changes, significant functional impairment, or inadequate response to Tier 2)

For cats with severe OA or those who do not respond adequately to Tier 2 interventions, escalate therapy with additional pharmacologic or biologic options.

• Continue all Tier 1 and Tier 2 interventions.
• Consider frunevetmab, a felinized anti-nerve growth factor monoclonal antibody, administered as a monthly subcutaneous injection. A 2021 study in the Journal of Veterinary Internal Medicine demonstrated its efficacy in reducing pain and improving mobility in cats with OA. [11] Monitor for injection site reactions and, rarely, hypersensitivity.
• Add amantadine at 3-5 mg/kg once daily, used off-label for chronic pain. Amantadine is an NMDA receptor antagonist that may help with central sensitization. Allow 2-4 weeks to assess response.
• Consider referral for physical therapy or rehabilitation. Modalities such as therapeutic laser, passive range of motion exercises, and hydrotherapy may provide additional benefit. The 2021 AAFP Feline Senior Care Guidelines highlight the role of rehabilitation in managing chronic pain. [7]
• Recheck every 4-6 weeks until pain is adequately controlled, then every 3-6 months for ongoing monitoring.

Decision Algorithm for Treatment Escalation

A simple algorithm can guide clinicians through the decision-making process at each recheck.

1. Assess pain control: Administer the FMPI and compare the score to the previous visit. A decrease of 5 or more points indicates a meaningful improvement. If the score has not improved or has worsened, proceed to step 2.
2. Evaluate compliance: Ask the owner about medication administration, environmental modifications, and weight management. Poor compliance is a common cause of treatment failure. Address barriers such as difficulty medicating the cat or reluctance to change the home environment.
3. Check for adverse effects: Review the medication log for any signs of adverse effects, such as vomiting, diarrhea, decreased appetite, lethargy, or changes in thirst or urination. If adverse effects are present, consider reducing the dose, changing the medication, or discontinuing the drug.
4. Consider concurrent disease: Re-evaluate the cat for new or worsening concurrent conditions, such as chronic kidney disease, hyperthyroidism, or diabetes mellitus. These conditions can affect pain perception and drug metabolism. The 2020 review in the Veterinary Clinics of North America notes that many cats with OA have concurrent conditions that influence drug selection and dosing. [9]
5. Escalate therapy: If pain is not controlled, compliance is adequate, and no adverse effects or concurrent disease are present, escalate to the next tier of therapy. If the cat is already on Tier 3, consider referral to a veterinary pain specialist or rehabilitation center.

Record System for Tracking Treatment Response

A standardized record system is essential for tracking treatment response over time. The following table provides a template for recording key data points at each visit.

This record allows the clinician to quickly identify trends, such as a gradual increase in pain scores despite treatment, which may indicate disease progression or the need for therapy adjustment. Digital records with graphing capabilities can make these trends even more apparent.

Troubleshooting Common Treatment Failures

Even with a structured framework, treatment failures occur. The following troubleshooting guide addresses common scenarios.

Scenario 1: Cat refuses to take oral medication

• Possible causes: Pill aversion, bitter taste, stress of handling.
• Solutions: Use compounded liquid formulations or transdermal gels (though absorption may be variable). Hide medication in a small amount of palatable food or treat. Use a pill pocket or wrap the pill in a soft treat. Consider injectable options such as frunevetmab. The 2021 AAFP Feline Senior Care Guidelines recommend minimizing stress during medication administration. [7]

Scenario 2: Owner reports no improvement after 4 weeks of Tier 1 therapy

• Possible causes: Disease is more severe than initially assessed, owner is not implementing environmental modifications correctly, or the cat has a concurrent condition causing pain.
• Solutions: Re-administer the FMPI and perform a thorough physical examination. Review the environmental modifications with the owner and provide written instructions. Consider adding pharmacologic therapy (Tier 2). Rule out other causes of pain, such as dental disease or neoplasia.

Scenario 3: Cat develops vomiting or diarrhea after starting an NSAID

• Possible causes: NSAID intolerance, concurrent gastrointestinal disease, or drug interaction.
• Solutions: Discontinue the NSAID immediately. Provide supportive care, including antiemetics and gastrointestinal protectants if needed. Consider switching to a different NSAID (e.g., from meloxicam to robenacoxib) or using an alternative analgesic such as gabapentin or frunevetmab. The 2020 review in the Veterinary Clinics of North America emphasizes the importance of monitoring for gastrointestinal adverse effects. [9]

Scenario 4: Pain scores improve initially but then plateau or worsen

• Possible causes: Disease progression, development of tolerance to medication, or new concurrent disease.
• Solutions: Reassess the cat's overall health status, including renal function and thyroid levels. Consider escalating therapy to the next tier. Add an adjunctive analgesic such as amantadine or consider frunevetmab. Refer to a veterinary pain specialist if pain remains uncontrolled.

Scenario 5: Owner is unable to afford recommended therapies

• Possible causes: Financial constraints limiting access to medications, supplements, or rehabilitation.
• Solutions: Prioritize interventions with the highest impact for the lowest cost. Weight management and environmental modifications are relatively inexpensive and highly effective. Use generic medications when available. Consider less expensive joint supplements, such as omega-3 fatty acids from fish oil. Discuss payment plans or pet insurance options. The 2021 AAFP Feline Senior Care Guidelines acknowledge that cost can be a barrier to care. [7]

Comparison of Pharmacologic Options for Feline OA

The following table compares the key pharmacologic options for managing feline OA pain, including their mechanisms, dosing, monitoring requirements, and evidence levels.

The 2021 study in the Journal of Veterinary Internal Medicine provides evidence for frunevetmab efficacy. [11] The 2020 review in the Veterinary Clinics of North America discusses the limitations of pharmacologic options for feline OA. [9]

Professional Escalation Criteria for Treatment Failure

When a cat's pain remains uncontrolled despite appropriate escalation through all three tiers, referral to a specialist is indicated.

• Uncontrolled pain after 8-12 weeks of Tier 3 therapy: Refer to a veterinary pain specialist or a board-certified veterinary anesthesiologist with expertise in pain management.
• Suspected surgical disease: If imaging reveals a joint fracture, luxation, or other surgical condition, refer to a veterinary surgeon.
• Severe adverse drug reactions: If a cat experiences a severe adverse reaction, such as acute kidney injury or gastrointestinal perforation, discontinue the drug and provide supportive care. Consult with a veterinary internist or pharmacologist.
• Diagnostic uncertainty: If the diagnosis remains unclear after radiography and basic laboratory testing, consider referral for advanced imaging (CT or MRI) or a second opinion from a veterinary internist.
• Concurrent complex disease: If the cat has multiple concurrent conditions that complicate treatment, such as chronic kidney disease, hyperthyroidism, and diabetes mellitus, consult with a veterinary internist for coordinated management.

Limitations of the Decision Framework

This framework has several limitations that clinicians should recognize.

• Individual variability: Cats vary widely in their response to therapies. Some cats may respond well to Tier 1 interventions alone, while others may require Tier 3 therapies from the outset. The framework provides a starting point, but clinical judgment is essential.
• Owner factors: The success of any treatment plan depends heavily on owner compliance. Owners who are unable or unwilling to implement environmental modifications or administer medications may not achieve optimal outcomes. The 2021 AAFP Feline Senior Care Guidelines recommend clear communication and written instructions to improve compliance. [7]
• Limited evidence for some therapies: The evidence for gabapentin, amantadine, and many joint supplements in feline OA is limited. Clinicians should discuss the evidence (or lack thereof) with owners and document informed consent for off-label use.
• Cost and availability: Some therapies, such as frunevetmab and advanced imaging, may not be available or affordable for all owners. Clinicians should work with owners to develop a plan that fits their resources.
• Disease progression: OA is a progressive disease, and treatment needs may change over time. Regular reassessment is essential to adjust the plan as the disease advances. The 2025 review in the Journal of Feline Medicine and Surgery notes that fundamental questions remain about the natural history of feline OA. [8]

Safety Context for Treatment Decisions

Safety considerations should guide every treatment decision.

• Renal function: NSAIDs are contraindicated in cats with dehydration, hypotension, or pre-existing renal disease. Always assess hydration status and renal function before starting NSAID therapy. Monitor renal parameters regularly during long-term use.
• Hepatic function: Cats with hepatic impairment may have altered drug metabolism. Use NSAIDs with caution and consider alternative analgesics.
• Gastrointestinal health: NSAIDs can cause gastrointestinal ulceration and bleeding. Use the lowest effective dose and consider adding a gastrointestinal protectant in high-risk cats.
• Drug interactions: Gabapentin and amantadine can cause sedation and ataxia, particularly when used together or with other CNS depressants. Monitor for these effects and adjust doses as needed.
• Pregnancy and lactation: The safety of most OA therapies in pregnant or lactating cats has not been established. Use only when the benefits clearly outweigh the risks.

By following this structured decision framework, clinicians can systematically select, monitor, and adjust therapies for feline OA, improving outcomes while minimizing adverse effects. The framework should be adapted to each individual cat and updated as new evidence becomes available.

Frequently Asked Questions

What is the most common cause of osteoarthritis in cats?

Primary or idiopathic OA is most common, meaning no specific underlying cause is identified. Secondary OA can result from trauma, developmental abnormalities, or previous joint infection. The Merck Veterinary Manual provides an overview of joint disease in cats. [4]

How is feline osteoarthritis diagnosed?

Diagnosis is based on a combination of history, physical examination, and diagnostic imaging. Radiography is the most common imaging modality, but CT may be used for complex cases. Pain assessment tools like the Feline Musculoskeletal Pain Index help quantify pain and monitor treatment. The 2021 AAFP Feline Senior Care Guidelines recommend routine screening for OA in senior cats. [7]

What are the clinical signs of osteoarthritis in cats?

Common signs include reduced activity, reluctance to jump, stiffness after rest, decreased grooming, and changes in litter box use. These signs are often subtle and may be attributed to normal aging. The 2021 AAFP Feline Senior Care Guidelines emphasize the importance of owner education to recognize these changes. [7]

Can osteoarthritis in cats be cured?

No, OA is a progressive, degenerative disease that cannot be cured. However, it can be effectively managed with a multimodal approach that includes weight management, environmental modification, analgesics, and other therapies. The goal is to improve quality of life and slow disease progression.

What pain medications are safe for cats with osteoarthritis?

Only a few NSAIDs, such as meloxicam and robenacoxib, are approved for long-term use in cats. Gabapentin and amantadine are used off-label. Frunevetmab, a monoclonal antibody, is a newer option approved for OA pain. All medications should be used under veterinary supervision with regular monitoring. The 2021 study in the Journal of Veterinary Internal Medicine provides evidence for frunevetmab efficacy. [11]

Are joint supplements effective for cats with osteoarthritis?

Evidence for the efficacy of joint supplements is mixed. Some cats may benefit from glucosamine, chondroitin, or omega-3 fatty acids, but rigorous clinical trials are lacking. The Merck Veterinary Manual notes the limited evidence for these products. [4] Omega-3 fatty acids have the strongest evidence for anti-inflammatory effects.

How can I help my cat at home?

Provide ramps or steps to access elevated surfaces, use low-sided litter boxes, place food and water bowls at ground level, and provide soft bedding. Weight management is also critical. The 2021 AAFP Feline Senior Care Guidelines provide detailed recommendations for environmental modification. [7]

When should I take my cat to the vet for osteoarthritis?

If you notice any changes in your cat's activity, mobility, or behavior, schedule a veterinary visit. Early diagnosis and management can improve quality of life. The 2021 AAFP Feline Senior Care Guidelines recommend routine senior wellness exams every six months for cats over seven years of age. [7]

Related Veterinary Guides

• Cat
• Clinical Biochemistry Urinalysis
• Hypertrophic Cardiomyopathy In Cats
• Prescription Medicine For Cats
• Sneezing Cat Remedy

References and Further Reading

• www.merckvetmanual.com
• catvets.com
• www.acvim.org
• Merck Veterinary Manual. Merck Veterinary Manual.
• Animal Health and Welfare. World Organisation for Animal Health.
• Feline Osteoarthritis Management.. The Veterinary clinics of North America. Small animal practice, 2023.
• 2021 AAFP Feline Senior Care Guidelines.. Journal of feline medicine and surgery, 2021.
• Osteoarthritis in cats: what we know, and mostly, what we don't know. . . yet.. Journal of feline medicine and surgery, 2025.
• Feline Chronic Pain and Osteoarthritis.. The Veterinary clinics of North America. Small animal practice, 2020.
• Diagnosis and treatment of osteoarthritis.. Topics in companion animal medicine, 2010.
• Frunevetmab, a felinized anti-nerve growth factor monoclonal antibody, for the treatment of pain from osteoarthritis in cats.. Journal of veterinary internal medicine, 2021.
• The use of platelet rich plasma in the treatment of degenerative joint disease in cats: an exploratory case series. Frontiers in Veterinary Science, 2024.
• Feline chronic progressive polyarthritis associated with Feline Leukemia Virus (FeLV) infection: Case report. Revista Brasileira De Medicina Veterinaria, 2016.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.